# Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Study · id `cardio:ct-nct02343926` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02343926](<https://clinicaltrials.gov/study/NCT02343926>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02343926

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 443 participants.

## Technical summary

Registry record NCT02343926. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 443 participants (enrolled count; ClinicalTrials.gov record NCT02343926, source copy `cardio:ctgov-nct02343926-2016-05-18`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02343926, source copy `cardio:ctgov-nct02343926-2016-05-18`, retrieved 2026-10-26)
- Primary completion: 2016-04 (actual) (ClinicalTrials.gov record NCT02343926, source copy `cardio:ctgov-nct02343926-2016-05-18`, retrieved 2026-10-26)
- Completion: 2016-04 (actual) (ClinicalTrials.gov record NCT02343926, source copy `cardio:ctgov-nct02343926-2016-05-18`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT02343926, source copy `cardio:ctgov-nct02343926-2016-05-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02343926-2016-05-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): GEMIGLIPTIN LS15-0444
- Intervention (Drug): vildagliptin
- Intervention (Drug): metformin
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 895f36fc3d7a22537159c0428de69ed74ea89ea3d3490a7c04fa232e8f3a07c8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
